VISIUS iCT establishes level of intraoperative imaging previously
unavailable to surgeons
WINNIPEG, July 22, 2013 /CNW/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM)
("IMRIS" or the "Company") today announced US Food and Drug
Administration (FDA) 510K clearance to market VISIUS® iCT, the first and only ceiling-mounted intraoperative computed
tomography (iCT) on the market.
"This revolutionary IMRIS solution will be an essential part of the
hybrid operating room of the future, especially for the spinal and
neurosurgical market," said David Graves, IMRIS CEO. "VISIUS iCT
provides surgeons with on-demand CT imaging to enhance decision making,
and both guide and confirm implant placement. The spine surgery market
represents a new opportunity for IMRIS and VISIUS iCT establishes a
level of intraoperative imaging previously unavailable to surgeons and
VISIUS iCT is a state-of-the-art surgical theater that provides
personalized dose management together with diagnostic quality imaging
during the surgical procedure to assist surgeons in critical decision
making. The 64-slice scanner effortlessly moves into and out of the
operating room during surgery using ceiling-mounted rails to ease
workflow. This enables multiple room configurations to meet both
clinical requirements and increase utilization without compromising
image quality or exam speed.
Patient transport and the need for floor-mounted rails used in other
systems is eliminated which opens up valuable OR space and allows
unimpeded movement of surgical equipment and simplified infection
control. The system also offers the longest scanner travel range on the
In addition, VISIUS iCT features a suite of software applications such
as 3D volume rendering to aid in surgical planning and dose reduction
which considers each patient's unique characteristics and needs to
maximize image quality and minimize dose. "State-of-the-art dose
management is one of the keys to driving the adoption of iCT to guide
surgical procedures," Graves said.
The system software allows healthcare practitioners to visualize dosage
prior to scan and adjust settings based on the specific clinical need
with detailed dosage reports produced after each scan.
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions through its VISIUS Surgical Theatre - a
revolutionary, multifunctional surgical environment that provides
unmatched intraoperative vision to clinicians to assist in decision
making and enhance precision in treatment. The multi-room suites
incorporate diagnostic quality high-field MR, CT and angio modalities
accessed effortlessly in the operating room setting. VISIUS Surgical
Theatres serve the neurosurgical, cardiovascular and cerebrovascular
markets and have been selected by 54 leading medical institutions
around the world.
Image with caption: "VISIUS iCT: First ceiling-mounted intraoperative CT solution. (CNW Group/IMRIS Inc.)". Image available at: http://photos.newswire.ca/images/download/20130722_C8849_PHOTO_EN_29187.jpg
SOURCE: IMRIS Inc.
For further information:
Kelly McNeill, IMRIS Inc.
Tel: 763-203-6304 Email: email@example.com